Table 8 Data at randomization for simulation 2B
From: Preventing false discovery of heterogeneous treatment effect subgroups in randomized trials
Placebo | Treatment | ASD | |
|---|---|---|---|
n = 3000 | n = 3000 | ||
Age (years) | 68.1 (±10.1) | 68.1 (±10.0) | 0.01 |
Black race | |||
No | 2,090 (69.7%) | 2,154 (71.8%) | 0.05 |
Yes | 910 (30.3%) | 846 (28.2%) | 0.05 |
Systolic blood pressure (mm Hg) | 140.3 (±15.1) | 140.1 (±14.7) | 0.01 |
Diastolic blood pressure (mm Hg) | 78.2 (±12.1) | 77.6 (±12.1) | 0.05 |
Serum creatinine (mg/dl) | 1.1 (±0.3) | 1.1 (±0.3) | 0 |
eGFR (ml min–1 1.73 m–2) | 71.6 (±20.3) | 71.6 (±19.7) | 0 |
Statin use | |||
No | 1,748 (58.3%) | 1,718 (57.3%) | 0.02 |
Yes | 1,252 (41.7%) | 1,282 (42.7%) | 0.02 |
Aspirin use | |||
No | 1,512 (50.4%) | 1,439 (48.0%) | 0.05 |
Yes | 1,488 (49.6%) | 1,561 (52.0%) | 0.05 |
Framingham risk score | 25.2 (±11.9) | 25.0 (±11.9) | 0.02 |
Smoking status | |||
Never | 1,303 (43.4%) | 1,324 (44.1%) | 0.01 |
Former | 1,301 (43.4%) | 1,242 (41.4%) | 0.04 |
Current | 396 (13.2%) | 434 (14.5%) | 0.04 |